Table 2.
Results of the base-case analysis.
LY | QALY | Incremental QALY | Cost (RMB) | Incremental cost | ICER (RMB/QALY) | |
---|---|---|---|---|---|---|
Sunitinib | 2.83 | 2.13 | – | 762,572 | – | – |
Lenvatinib+Everolimus | 2.96 | 2.17 | 0.04 | 795,424 | 32,851 | 776,202 |
Lenvatinib+Pembrolizumab | 3.44 | 2.60 | 0.47 | 2,015,702 | 1,253,130 | 2,657,025 |
LY, life year; QALY, quality-adjusted life-year; ICER, incremental cost-effectiveness ratio.